| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |